Niemann-Pick Disease Type E

Mendelian MONDO:0020384 Pathograph 3 Show in embeddings browser Sphingolipidosis Lysosomal Storage Disorder

Niemann-Pick disease type E is a historical, ill-defined nosologic label that was applied to rare (mostly adult) patients with Niemann-Pick-like lipid storage who did not fit the classic types A, B, or C. These patients showed hepatomegaly, foamy macrophage infiltration of tissues and bone marrow, partial acid sphingomyelinase deficiency, and sphingomyelin accumulation with variable neurological deterioration. In the molecular era, Niemann-Pick disease has been redefined as acid sphingomyelinase deficiency (ASMD; SMPD1) and Niemann-Pick disease type C (NPC1/NPC2), and the nosology of types D and E is no longer used. Patients historically labeled "type E" should be re-classified to ASMD, NPC, or another lysosomal disorder using enzyme activity, biomarkers, and molecular testing.

Ask OpenScientist

Ask a research question about Niemann-Pick Disease Type E. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Pathophys.
2
Phenotypes
1
Gaps
3
Pathograph
2
Differentials
1
Deep Research
🔗

Mappings

MONDO
MONDO:0020384 Niemann-Pick disease type E
skos:exactMatch MONDO
Primary MONDO identifier for this historical Niemann-Pick disease type E label.
📘

Definitions

1
Historical (deprecated) definition of Niemann-Pick disease type E
Niemann-Pick disease type E was a historical label for patients with Niemann-Pick-like lipid storage (hepatomegaly, foam cells, partial acid sphingomyelinase deficiency, sphingomyelin accumulation, neurological deterioration) who did not fit types A, B, or C. The label is obsolete; modern diagnosis reclassifies such patients into ASMD or NPC.
CASE_DEFINITION Disease-level historical case definition flagged as a deprecated nosologic label.
Show evidence (1 reference)
PMID:28164782 SUPPORT Human Clinical
"The nosology of types D and E NPD are no longer used."
Authoritative review states the type D and E nosology is obsolete.
?

Discussions and Knowledge Gaps

1
Is "Niemann-Pick disease type E" a distinct disease entity, or an obsolete historical label whose cases should be reclassified into acid sphingomyelinase deficiency (SMPD1), Niemann-Pick disease type C (NPC1/NPC2), or another lysosomal disorder?
KNOWLEDGE GAP OPEN gap_npe_obsolete_nosology
Attached to
pathophysiology#Lysosomal Sphingomyelin and Lipid Storage with Foam Cell Infiltration
Authoritative review states the nosology of types D and E Niemann-Pick disease is no longer used, and later case literature notes the biochemical nature of "type E" remains unclarified. The MONDO term is retained for historical mapping, but the entity has no established causal gene and should be resolved by enzyme, biomarker, and molecular testing into a modern diagnosis.
⚙

Pathophysiology

1
Lysosomal Sphingomyelin and Lipid Storage with Foam Cell Infiltration
Patients historically labeled type E showed partial acid sphingomyelinase deficiency with sphingomyelin accumulation and foamy macrophage (foam cell) infiltration of tissues and bone marrow, within the broader Niemann-Pick storage spectrum. The precise biochemical and molecular basis of the "type E" label was never clarified and is now subsumed under ASMD or NPC.
macrophage CL:0000235
lysosome GO:0005764
Downstream
Hepatomegaly Visceral sphingomyelin storage and foamy macrophage infiltration produce hepatomegaly in the historical type E phenotype.
Neurodegeneration Historical type E cases with lipid storage also showed chronic neurological deterioration, represented here as neurodegeneration.
Show evidence (1 reference)
PMID:28164782 SUPPORT Human Clinical
"These patients presented with hepatomegaly, foamy macrophage infiltration into tissues and bone marrow, partial deficiency of ASM activity, and moderate accumulation of sphingomyelin, but also exhibited chronic and often severe neurological deterioration."
Describes the storage pathology of the patients historically grouped as types C, D, or E.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Niemann-Pick Disease Type E Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

2
Digestive 1
Hepatomegaly Hepatomegaly HP:0002240
Show evidence (1 reference)
PMID:28164782 SUPPORT Human Clinical
"These patients presented with hepatomegaly, foamy macrophage infiltration into tissues and bone marrow"
Hepatomegaly with foam-cell infiltration was a feature of these patients.
Other 1
Neurodegeneration Neurodegeneration HP:0002180
Show evidence (1 reference)
PMID:28164782 SUPPORT Human Clinical
"but also exhibited chronic and often severe neurological deterioration"
Chronic, often severe neurological deterioration was part of the historical phenotype.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Niemann-Pick Disease Type E:

Acid sphingomyelinase deficiency (Niemann-Pick type B) MONDO:0011871
Overlapping Features The chronic visceral form of ASMD (SMPD1), one of the modern entities into which historical type E cases should be reclassified.
Distinguishing Features
  • Defined molecularly by SMPD1 variants and reduced acid sphingomyelinase activity, providing a precise diagnosis where "type E" did not.
Show evidence (1 reference)
PMID:28164782 SUPPORT Human Clinical
"The nosology of types D and E NPD are no longer used."
Type E is obsolete; such patients are reclassified to ASMD or NPC.
Niemann-Pick disease type C MONDO:0018982
Overlapping Features The cholesterol-trafficking disorder (NPC1/NPC2) into which some historical adult Niemann-Pick cases are reclassified.
Distinguishing Features
  • Defined molecularly by NPC1/NPC2 defects of intracellular cholesterol transport.
Show evidence (1 reference)
PMID:28164782 SUPPORT Human Clinical
"We now know that type C NPD is due to defects in two distinct cholesterol-binding proteins (NPC1 and NPC2)."
Type C is the molecularly defined cholesterol-trafficking entity replacing parts of the historical C/D/E grouping.
{ }

Source YAML

click to show 
name: Niemann-Pick Disease Type E
creation_date: "2026-06-13T00:00:00Z"
description: >-
  Niemann-Pick disease type E is a historical, ill-defined nosologic label that was
  applied to rare (mostly adult) patients with Niemann-Pick-like lipid storage who did not
  fit the classic types A, B, or C. These patients showed hepatomegaly, foamy macrophage
  infiltration of tissues and bone marrow, partial acid sphingomyelinase deficiency, and
  sphingomyelin accumulation with variable neurological deterioration. In the molecular
  era, Niemann-Pick disease has been redefined as acid sphingomyelinase deficiency (ASMD;
  SMPD1) and Niemann-Pick disease type C (NPC1/NPC2), and the nosology of types D and E is
  no longer used. Patients historically labeled "type E" should be re-classified to ASMD,
  NPC, or another lysosomal disorder using enzyme activity, biomarkers, and molecular
  testing.
category: Mendelian
disease_term:
  preferred_term: Niemann-Pick disease type E
  term:
    id: MONDO:0020384
    label: Niemann-Pick disease type E
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0020384
      label: Niemann-Pick disease type E
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO identifier for this historical Niemann-Pick disease type E label.
synonyms:
- Niemann-Pick disease, type E
- NPD type E
parents:
- Sphingolipidosis
- Lysosomal Storage Disorder
pathophysiology:
- name: Lysosomal Sphingomyelin and Lipid Storage with Foam Cell Infiltration
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >-
    Patients historically labeled type E showed partial acid sphingomyelinase deficiency
    with sphingomyelin accumulation and foamy macrophage (foam cell) infiltration of
    tissues and bone marrow, within the broader Niemann-Pick storage spectrum. The precise
    biochemical and molecular basis of the "type E" label was never clarified and is now
    subsumed under ASMD or NPC.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:28164782
    reference_title: "Types A and B Niemann-Pick disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These patients presented with hepatomegaly, foamy macrophage infiltration into tissues and bone marrow, partial deficiency of ASM activity, and moderate accumulation of sphingomyelin, but also exhibited chronic and often severe neurological deterioration."
    explanation: "Describes the storage pathology of the patients historically grouped as types C, D, or E."
  downstream:
  - target: Hepatomegaly
    description: >-
      Visceral sphingomyelin storage and foamy macrophage infiltration produce
      hepatomegaly in the historical type E phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28164782
      reference_title: "Types A and B Niemann-Pick disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These patients presented with hepatomegaly, foamy macrophage infiltration into tissues and bone marrow"
      explanation: This directly links hepatomegaly with foam-cell storage pathology in historical type E patients.
  - target: Neurodegeneration
    description: >-
      Historical type E cases with lipid storage also showed chronic neurological
      deterioration, represented here as neurodegeneration.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28164782
      reference_title: "Types A and B Niemann-Pick disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "but also exhibited chronic and often severe neurological deterioration"
      explanation: This directly links the historical storage phenotype to chronic neurological deterioration.
phenotypes:
- name: Hepatomegaly
  description: Hepatomegaly from foamy macrophage storage.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:28164782
    reference_title: "Types A and B Niemann-Pick disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These patients presented with hepatomegaly, foamy macrophage infiltration into tissues and bone marrow"
    explanation: "Hepatomegaly with foam-cell infiltration was a feature of these patients."
- name: Neurodegeneration
  description: Chronic, often severe neurological deterioration was reported.
  phenotype_term:
    preferred_term: Neurodegeneration
    term:
      id: HP:0002180
      label: Neurodegeneration
  evidence:
  - reference: PMID:28164782
    reference_title: "Types A and B Niemann-Pick disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "but also exhibited chronic and often severe neurological deterioration"
    explanation: "Chronic, often severe neurological deterioration was part of the historical phenotype."
differential_diagnoses:
- name: Acid sphingomyelinase deficiency (Niemann-Pick type B)
  description: >-
    The chronic visceral form of ASMD (SMPD1), one of the modern entities into which
    historical type E cases should be reclassified.
  disease_term:
    preferred_term: Niemann-Pick disease type B
    term:
      id: MONDO:0011871
      label: Niemann-Pick disease type B
  distinguishing_features:
  - Defined molecularly by SMPD1 variants and reduced acid sphingomyelinase activity, providing a precise diagnosis where "type E" did not.
  evidence:
  - reference: PMID:28164782
    reference_title: "Types A and B Niemann-Pick disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The nosology of types D and E NPD are no longer used."
    explanation: "Type E is obsolete; such patients are reclassified to ASMD or NPC."
- name: Niemann-Pick disease type C
  description: >-
    The cholesterol-trafficking disorder (NPC1/NPC2) into which some historical adult
    Niemann-Pick cases are reclassified.
  disease_term:
    preferred_term: Niemann-Pick disease type C
    term:
      id: MONDO:0018982
      label: Niemann-Pick disease type C
  distinguishing_features:
  - Defined molecularly by NPC1/NPC2 defects of intracellular cholesterol transport.
  evidence:
  - reference: PMID:28164782
    reference_title: "Types A and B Niemann-Pick disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We now know that type C NPD is due to defects in two distinct cholesterol-binding proteins (NPC1 and NPC2)."
    explanation: "Type C is the molecularly defined cholesterol-trafficking entity replacing parts of the historical C/D/E grouping."
definitions:
- name: Historical (deprecated) definition of Niemann-Pick disease type E
  definition_type: CASE_DEFINITION
  description: >-
    Niemann-Pick disease type E was a historical label for patients with Niemann-Pick-like
    lipid storage (hepatomegaly, foam cells, partial acid sphingomyelinase deficiency,
    sphingomyelin accumulation, neurological deterioration) who did not fit types A, B, or
    C. The label is obsolete; modern diagnosis reclassifies such patients into ASMD or NPC.
  scope: Disease-level historical case definition flagged as a deprecated nosologic label.
  evidence:
  - reference: PMID:28164782
    reference_title: "Types A and B Niemann-Pick disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The nosology of types D and E NPD are no longer used."
    explanation: "Authoritative review states the type D and E nosology is obsolete."
discussions:
- discussion_id: gap_npe_obsolete_nosology
  prompt: >-
    Is "Niemann-Pick disease type E" a distinct disease entity, or an obsolete historical
    label whose cases should be reclassified into acid sphingomyelinase deficiency (SMPD1),
    Niemann-Pick disease type C (NPC1/NPC2), or another lysosomal disorder?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Lysosomal Sphingomyelin and Lipid Storage with Foam Cell Infiltration
  rationale: >-
    Authoritative review states the nosology of types D and E Niemann-Pick disease is no
    longer used, and later case literature notes the biochemical nature of "type E" remains
    unclarified. The MONDO term is retained for historical mapping, but the entity has no
    established causal gene and should be resolved by enzyme, biomarker, and molecular
    testing into a modern diagnosis.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Niemann–Pick Disease Type E (historical): Comprehensive Disease Characteristics Report
Edison Scientific Literature 43 citations 2026-06-13T14:18:22.264408

Niemann–Pick Disease Type E (historical): Comprehensive Disease Characteristics Report

Executive summary (current understanding)

Niemann–Pick disease “type E” (NPDE) is best understood as a historical, ill-defined nosologic label applied to rare, mostly adult presentations of Niemann–Pick–like storage disease. Modern expert sources emphasize that the molecular era split Niemann–Pick disorders into acid sphingomyelinase deficiency (ASMD; SMPD1; historically types A/B) and Niemann–Pick disease type C (NPC; NPC1/NPC2; historically type C and type D), and that “The nosology of types D and E NPD are no longer used.” (schuchman2017typesaand pages 1-3). A 2016 case report still used “type E” for an adult with Niemann–Pick cells and normal leukocyte acid sphingomyelinase and concluded that “the biochemical nature of type E still awaits clarification.” (zheng2016casereportrenal pages 3-5). Accordingly, a knowledge-base entry for “NP type E” should explicitly record that it is an obsolete label and that modern diagnosis should re-classify cases into ASMD, NPC, or another lysosomal disorder using enzyme activity, biomarkers, and molecular testing. (schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14)

Key concepts and definitions (with modern reclassification)

What is the disease?

Historically, “Niemann–Pick disease” referred to patients with lipid storage and foam cells and overlapping clinical features such as hepatosplenomegaly, pulmonary insufficiency, and/or CNS involvement. (schuchman2017typesaand pages 1-3)

Modern work established two main metabolic etiologies: - ASMD (historical NPD types A and B): due to deficient acid sphingomyelinase (ASM) activity caused by SMPD1 mutations. (schuchman2017typesaand pages 1-3) - NPC (historical NPD type C; type D now included): due to defective intracellular cholesterol transport caused by NPC1 or NPC2 defects. (schuchman2017typesaand pages 1-3, patinoescobar2019niemannpickdiseasean pages 1-2)

“Type E” was historically used for some intermediate or adult cases, but authoritative review states it is no longer used (schuchman2017typesaand pages 1-3), and later case literature highlights it remains biochemically unclear (zheng2016casereportrenal pages 3-5).

Key identifiers (requested)

Evidence retrieved here did not provide an authoritative MONDO/MeSH/ICD/Orphanet identifier specifically for “Niemann–Pick disease type E.” Because “type E” is obsolete, modern resources typically index patients under ASMD or NPC rather than NPDE. (schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 4-5)

Ontology suggestion (to implement in KB, with uncertainty): treat “Niemann–Pick disease type E” as a historical synonym / deprecated term and map to parent concept “Niemann–Pick disease” with recommended reclassification to ASMD or NPC based on testing.

Synonyms / alternative names

  • “Niemann–Pick disease type E” (historical) (zheng2016casereportrenal pages 3-5, schuchman2017typesaand pages 1-3)
  • Many “type E” adult cases are described alongside sea-blue histiocytes/foamy macrophages in older literature; in modern practice such pathology may occur in ASMD and other lysosomal disorders and is not diagnostic alone. (geberhiwot2023consensusclinicalmanagement pages 9-11)

Evidence source type

The “type E” concept in the retrieved evidence is derived primarily from individual case reports / historical classification rather than aggregated, molecularly curated disease resources. (zheng2016casereportrenal pages 3-5, schuchman2017typesaand pages 1-3)

Etiology

Disease causal factors

NP type E (legacy): - A 2016 case report describes NP type E as rare and states that “the biochemical nature of type E still awaits clarification.” (zheng2016casereportrenal pages 3-5) - In that case, leukocyte ASM activity was normal, suggesting it did not fit classic ASMD A/B. (zheng2016casereportrenal pages 1-3)

Modern molecular entities that “type E” cases may represent: - ASMD: caused by pathogenic variants in SMPD1; diagnosis requires demonstrating deficient ASM activity and confirming genotype for counseling. (geberhiwot2023consensusclinicalmanagement pages 4-5, geberhiwot2023consensusclinicalmanagement pages 9-11, geberhiwot2023consensusclinicalmanagement pages 13-14) - NPC: caused by NPC1 or NPC2 mutations; NPC1 accounts for ~95% of families in a major review. (patinoescobar2019niemannpickdiseasean pages 1-2)

Risk factors / protective factors / gene–environment interaction

No NPDE-specific genetic or environmental risk/protective factors were identified in the retrieved evidence; NPDE is too ill-defined and rare for robust epidemiology. (zheng2016casereportrenal pages 3-5, schuchman2017typesaand pages 1-3)

Phenotypes

NP type E phenotype (what is known)

From a 2016 adult case report/literature framing: - NP type E described as an uncommon adult form, “possibly non-neuronopathic,” with “preserved mental status,” “variable hepatosplenomegaly,” and longer survival in historical descriptions. (zheng2016casereportrenal pages 1-3) - Renal involvement is described as rare but present in the reported case: kidney biopsy showed lipid storage/foam cells and EM showed lipid deposits in endothelial cells and podocytes, with proteinuria and renal insufficiency. (zheng2016casereportrenal pages 1-3) - Bone marrow Niemann–Pick cells supported diagnosis. (zheng2016casereportrenal pages 1-3, zheng2016casereportrenal pages 3-5)

Phenotype ontology suggestions (HPO; based on reported signs in retrieved evidence): - Splenomegaly (HP:0001744) - Hepatomegaly (HP:0002240) - Foam cells / lipid-laden macrophages (often captured under storage disease histopathology terms) - Proteinuria (HP:0000093) - Renal insufficiency (HP:0000083) - Ascites (HP:0001541)

Frequency estimates for NPDE are not available from the retrieved evidence (single case report + narrative). (zheng2016casereportrenal pages 1-3)

Phenotypes in modern entities (for reclassification)

Because NPDE is obsolete, phenotype expectations should follow the reclassified entity: - NPC registry data (INPDR, 2022) report common neurologic manifestations: cognitive impairment 78.5%, dysarthria 75.9%, ataxia 75.9%, VSGP 70.9%, dysphagia 69.6%; and splenomegaly recorded in 80% of adult-onset patients. (bolton2022clinicaldiseasecharacteristics pages 6-8) - ASMD guideline notes common manifestations include hepatosplenomegaly, interstitial lung disease, cytopenias, and dyslipidemia with low HDL and elevated cholesterol/triglycerides. (geberhiwot2023consensusclinicalmanagement pages 9-11)

Genetic / molecular information

Causal genes (modern mapping)

  • ASMD: SMPD1 (acid sphingomyelinase). ASMD is explicitly synonymous with Niemann–Pick disease types A, B and A/B. (geberhiwot2023consensusclinicalmanagement pages 1-2)
  • NPC: NPC1 or NPC2 mutations; NPC1 ~95% of families in a major review. (patinoescobar2019niemannpickdiseasean pages 1-2)

Pathogenic variants (recent, concrete examples)

ASMD (2024 Polish cohort): seven SMPD1 variants were identified; missense variants comprised 71% of alleles. (lipinski2024chronicacidsphingomyelinase pages 1-2)

NPC (INPDR 2022): p.I1061T variant was common (reported frequency in extracted registry summary). (bolton2022clinicaldiseasecharacteristics pages 6-8)

Modifier genes / epigenetics / chromosomal abnormalities No NPDE-specific modifier genes or epigenetic/chromosomal drivers were identified in the retrieved evidence.

Environmental information

No NPDE-specific environmental or lifestyle contributors were identified in the retrieved evidence.

Mechanism / pathophysiology

NP type E (legacy)

Mechanism is not established; the 2016 report explicitly indicates uncertainty and lack of a defined biochemical defect for type E. (zheng2016casereportrenal pages 3-5)

ASMD (SMPD1 / ASM deficiency)

ASMD is a lysosomal storage disease with sphingomyelin accumulation in tissues; ASMD pathology includes foam cell infiltration and multisystem involvement. (schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 9-11)

Diagnostic biomarker/pathophysiology linkage: - Lyso-sphingomyelin (lyso-SM) is described as the “most specific biomarker for ASMD” and is elevated in ASMD (lyso-SM509/PPCS may also be elevated but is seen in NPC too), supporting both diagnosis and monitoring. (geberhiwot2023consensusclinicalmanagement pages 11-13)

NPC (NPC1/NPC2 cholesterol trafficking defect)

NPC is described as a “cellular cholesterol trafficking defect,” with filipin staining of fibroblasts demonstrating lysosomal unesterified cholesterol accumulation. (patinoescobar2019niemannpickdiseasean pages 1-2)

GO term suggestions (mechanisms): - Lysosomal lipid catabolic process; cholesterol transport; endosome-to-lysosome transport; autophagy-related processes.

Cell type suggestions (CL): - Macrophage (foam cell); hepatocyte; alveolar macrophage; neurons (for neuronopathic forms).

Anatomical structures affected

NP type E (case-based)

  • Reticuloendothelial tissues (bone marrow, liver, spleen) and kidney were involved in the 2016 case report, with lipid-laden cells and EM lipid deposits in renal structures. (zheng2016casereportrenal pages 1-3)

UBERON suggestions: spleen, liver, kidney, bone marrow.

ASMD/NPC (modern)

  • ASMD frequently affects spleen/liver/lung and can involve multiple organ systems. (geberhiwot2023consensusclinicalmanagement pages 9-11)
  • NPC is neurovisceral, with systemic signs often preceding neurologic involvement. (patinoescobar2019niemannpickdiseasean pages 1-2)

Temporal development

NP type E

Adult-onset is emphasized in type E descriptions; progression details and staging are not standardized due to rarity and obsolete classification. (zheng2016casereportrenal pages 1-3)

NPC (context)

INPDR (2022) includes adult-onset forms (20.8% adult neurological onset) and shows neurologic manifestations common across onset strata. (bolton2022clinicaldiseasecharacteristics pages 6-8)

ASMD (context)

ASMD spectrum includes chronic visceral adult presentations and a continuum of severity. (geberhiwot2023consensusclinicalmanagement pages 1-2)

Inheritance and population

NP type E

Inheritance is not well characterized for the legacy label. The 2016 report frames Niemann–Pick disease in general as autosomal recessive but indicates type E mechanism is unclear. (zheng2016casereportrenal pages 1-3, zheng2016casereportrenal pages 3-5)

Modern entities (for KB reclassification)

  • ASMD: autosomal recessive due to SMPD1 mutations. (geberhiwot2023consensusclinicalmanagement pages 1-2)
  • NPC: autosomal recessive due to NPC1 or NPC2 mutations. (patinoescobar2019niemannpickdiseasean pages 1-2)

Robust NPDE prevalence/incidence statistics were not identified.

Diagnostics

Key point: avoid “type E” as final diagnosis

Because “type E” is obsolete, modern diagnosis should proceed by distinguishing ASMD versus NPC (and other lysosomal disorders) with enzyme assay/biomarkers/genetics. (schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14)

ASMD diagnostic workflow (2023 consensus)

  • Perform ASM enzyme assay when ASMD suspected; diagnosis established by markedly reduced ASM activity in leukocytes or fibroblasts; DBS is increasingly used but should be confirmed due to false negatives/pre-analytical limitations. (geberhiwot2023consensusclinicalmanagement pages 9-11)
  • SMPD1 sequencing is recommended to confirm diagnosis and enable counseling; VUS require functional evidence of enzyme deficiency. (geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14)
  • Biomarkers: lyso-SM is most specific; multiplex MS/MS panels measuring lyso-SM, PPCS, lyso-Gb1 help differential diagnosis among ASMD, Gaucher, and NPC. (geberhiwot2023consensusclinicalmanagement pages 11-13)

NPC diagnostic workflow (2010 review)

  • Primary lab diagnosis uses living skin fibroblasts to demonstrate lysosomal cholesterol accumulation after filipin staining; genotyping is useful to confirm especially in variant biochemical phenotypes. (patinoescobar2019niemannpickdiseasean pages 1-2)

“Type E” diagnostic clues in the 2016 case report

  • Bone marrow Niemann–Pick cells, normal leukocyte ASM activity (distinguishing from types A/B), and elevated chitotriosidase were used in the case report to label NP type E. (zheng2016casereportrenal pages 1-3)

Outcome / prognosis

No NPDE-specific survival estimates were identified in the retrieved evidence. The 2016 report suggests longer survival than infantile forms in historical descriptions, but does not quantify survival. (zheng2016casereportrenal pages 1-3)

Treatment

NP type E (legacy)

The 2016 case report states no effective disease-specific therapy and describes supportive/symptomatic management. (zheng2016casereportrenal pages 1-3)

Modern disease-modifying therapies (relevant after reclassification)

ASMD: - 2023 ASMD guideline describes olipudase alfa (human recombinant ASM) as the first/only disease-modifying therapy and indicates it for long-term treatment of non-CNS manifestations, with approvals in multiple regions. (geberhiwot2023consensusclinicalmanagement pages 17-19) - A 2023 case report notes FDA approval in 2022 for olipudase alfa to treat non-CNS manifestations of ASM deficiency (NPD A/B/A-B) and reports biomarker confirmation via markedly elevated lyso-SM509 and low ASM activity. (sanchezvargas2023personalizedprecisionmedicine pages 3-4) - 2024 Polish cohort notes EMA approval (Dec 2020) and local availability timeline (Poland April 2024). (lipinski2024chronicacidsphingomyelinase pages 1-2)

NPC: - INPDR 2022 reported miglustat use in 62.4% of patients (85/203), mean duration just over 4 years. (bolton2022clinicaldiseasecharacteristics pages 6-8)

MAXO suggestions: - Enzyme replacement therapy; genetic counseling; supportive care; lipid/metabolic monitoring; pulmonary supportive management.

Prevention

No NPDE-specific prevention strategies were identified. For ASMD/NPC, prevention is primarily genetic counseling and family-based carrier/prenatal testing enabled by molecular confirmation. (geberhiwot2023consensusclinicalmanagement pages 13-14)

Other species / natural disease

Direct NPDE natural disease in other species was not identified. NPC has described feline/canine models with similar neurologic phenotypes (tremor/ataxia). (hovakimyan2013olfactorydeficitsin pages 1-2)

Model organisms (research applications)

ASMD (Niemann–Pick A/B) models

  • ASM knockout (ASMKO; Smpd1) mice recapitulate biochemical deficiency, systemic foam cells, motor impairment (ataxia/tremor), progressive neurodegeneration, and shortened lifespan (~6–8 months). (sarna2001patternedcerebellarpurkinje pages 1-2)
  • Purkinje cell degeneration is patterned and progressive; studies describe zebrin II–negative Purkinje cells lost earlier, with later involvement of other zones. (sarna2001patternedcerebellarpurkinje pages 2-4)
  • ASMKO models also show inflammatory disease contributing to pulmonary and neurologic phenotypes and disruption of ceramide-mediated signaling. (schuchman2017typesaand pages 6-8)

NPC models

  • Npc1−/− mouse models show neurodegeneration, hepatosplenomegaly, weight loss and early death (about 10 weeks in one description), and lysosomal accumulation of unesterified cholesterol and gangliosides. (hovakimyan2013olfactorydeficitsin pages 1-2)
  • Therapeutic testing example: allopregnanolone treatment in NPC mice delayed demyelination and increased survival. (ahmad2005allopregnanolonetreatmentboth pages 1-2)

Recent developments and real-world implementations (prioritizing 2023–2024)

Modern NPDE-relevant “developments” largely concern ASMD and NPC, because NPDE is obsolete.

  • Clinical management standardization (2023): A 2023 Orphanet Journal consensus guideline provides diagnostic and management statements for ASMD, including modern MS/MS enzyme assays, lyso-SM biomarkers, and SMPD1 sequencing for confirmation and counseling. (geberhiwot2023consensusclinicalmanagement pages 9-11, geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14)
  • Real-world care burden (2023): US claims analysis (IQVIA Open Claims) quantified high multi-system healthcare use for ASMD type B with frequent liver/spleen/lung involvement and substantial hospitalization burden. (pulikottiljacob2023healthcareserviceuse pages 1-2, pulikottiljacob2023healthcareserviceuse pages 11-13)
  • Biomarker-forward pediatric practice (2024): Polish pediatric ASMD follow-up highlights dried blood spot lyso-SM elevation, universal low HDL and low vitamin D, and 71% missense-allele burden in SMPD1 among 7 followed patients. (lipinski2024chronicacidsphingomyelinase pages 1-2, lipinski2024chronicacidsphingomyelinase pages 4-6)

Expert opinions / authoritative analysis

  • Nosology: Schuchman & Desnick (2017) explicitly conclude: “The nosology of types D and E NPD are no longer used.” (schuchman2017typesaand pages 1-3)
  • Guideline framing: 2023 consensus guidelines adopt ASMD terminology to distinguish SMPD1-related disease from NPC and provide evidence-graded statements on diagnosis and management. (geberhiwot2023consensusclinicalmanagement pages 4-5, geberhiwot2023consensusclinicalmanagement pages 9-11)

Relevant statistics and data (recent)

A summary of the most directly usable 2022–2024 quantitative data is provided in Artifact 02. (bolton2022clinicaldiseasecharacteristics pages 6-8, pulikottiljacob2023healthcareserviceuse pages 1-2, lipinski2024chronicacidsphingomyelinase pages 4-6)

Historical label Modern mapping / status Gene(s) / biochemical defect Representative clinical features Hallmark diagnostics Key source
Niemann-Pick type A Now grouped under acid sphingomyelinase deficiency (ASMD); infantile neurovisceral end of ASMD spectrum SMPD1; deficient acid sphingomyelinase (ASM) activity causing sphingomyelin storage Infantile onset, massive hepatosplenomegaly, profound CNS involvement, death usually by 2–3 years Low ASM activity in leukocytes/fibroblasts; SMPD1 molecular testing Schuchman & Desnick, 2017, Mol Genet Metab, doi:10.1016/j.ymgme.2016.12.008, https://doi.org/10.1016/j.ymgme.2016.12.008 (schuchman2017typesaand pages 1-3)
Niemann-Pick type B Now grouped under ASMD; chronic visceral end of ASMD spectrum SMPD1; deficient ASM activity Hepatosplenomegaly, lung disease/pulmonary insufficiency, usually no CNS signs, survival into adulthood common Low ASM activity; SMPD1 testing; newer screening biomarkers include lyso-sphingomyelin in DBS Geberhiwot et al., 2023, Orphanet J Rare Dis, doi:10.1186/s13023-023-02686-6, https://doi.org/10.1186/s13023-023-02686-6; Lipiński et al., 2024, Adv Clin Exp Med, doi:10.17219/acem/193696, https://doi.org/10.17219/acem/193696 (geberhiwot2023consensusclinicalmanagement pages 4-5, geberhiwot2023consensusclinicalmanagement pages 1-2, lipinski2024chronicacidsphingomyelinase pages 1-2)
Niemann-Pick type A/B (intermediate) Modern ASMD continuum includes chronic neurovisceral/intermediate forms rather than a strict separate legacy subtype SMPD1; partial ASM deficiency Visceral disease with variable neurologic involvement ASM assay plus SMPD1 sequencing Geberhiwot et al., 2023, doi:10.1186/s13023-023-02686-6, https://doi.org/10.1186/s13023-023-02686-6 (geberhiwot2023consensusclinicalmanagement pages 4-5, geberhiwot2023consensusclinicalmanagement pages 1-2)
Niemann-Pick type C Separate entity: Niemann-Pick disease type C (NPC), not ASMD NPC1 (~95% of families) or NPC2; defective intracellular cholesterol trafficking / cholesterol esterification abnormalities Progressive neurovisceral disease; splenomegaly, ataxia, dysarthria, dysphagia, cognitive decline, vertical supranuclear gaze palsy; adult-onset forms occur Filipin staining of cultured fibroblasts showing unesterified cholesterol accumulation; NPC1/NPC2 genotyping Vanier, 2010, Orphanet J Rare Dis, doi:10.1186/1750-1172-5-16, https://doi.org/10.1186/1750-1172-5-16; Bolton et al., 2022, doi:10.1186/s13023-022-02200-4, https://doi.org/10.1186/s13023-022-02200-4 (bolton2022clinicaldiseasecharacteristics pages 6-8, patinoescobar2019niemannpickdiseasean pages 1-2)
Niemann-Pick type D Obsolete historical label; patients now recognized within NPC Historically separated geographically/clinically; molecularly falls within NPC1/NPC2-related cholesterol trafficking disease NPC-like neurovisceral phenotype Same as NPC: filipin testing and NPC1/NPC2 testing Schuchman & Desnick, 2017, doi:10.1016/j.ymgme.2016.12.008, https://doi.org/10.1016/j.ymgme.2016.12.008 (schuchman2017typesaand pages 1-3)
Niemann-Pick type E Historical/ill-defined and obsolete label; used for rare adult patients with splenomegaly/sea-blue histiocytosis or mixed features; modern sources indicate D/E nosology is no longer used, and older D/E/C cases were later split into ASMD (SMPD1) vs NPC (NPC1/NPC2) based on biochemistry/genetics No single validated molecular basis for the legacy label; older reports described normal leukocyte ASM in some putative type E cases, underscoring heterogeneity Adult onset; variable hepatosplenomegaly/splenomegaly, sometimes preserved cognition, occasionally neurologic or multisystem involvement; very rare renal involvement reported Historically bone marrow Niemann-Pick/foam cells and exclusion of classic A/B; today recommended workup is ASM enzyme assay + SMPD1 testing, and if not ASMD, NPC biochemical/genetic testing Schuchman & Desnick, 2017, doi:10.1016/j.ymgme.2016.12.008, https://doi.org/10.1016/j.ymgme.2016.12.008; Zheng et al., 2016, case report/lit review, URL not available in provided context (zheng2016casereportrenal pages 1-3, zheng2016casereportrenal pages 3-5, schuchman2017typesaand pages 1-3)

Table: This table summarizes how historical Niemann-Pick subtype labels map to current molecularly defined entities. It is especially useful for clarifying why the legacy 'type E' designation is now considered obsolete and how modern diagnosis distinguishes ASMD from NPC.

Entity / framing Onset / course Reported clinical characteristics Key diagnostic findings Evidence type Notes on uncertainty
Niemann-Pick disease “type E” (Zheng et al. 2016 case report) Adult onset; rare, poorly characterized; described as uncommon adult form with longer survival Variable hepatosplenomegaly; preserved mental status in historical description; in the reported patient, renal involvement with renal failure and ascites, diffuse foam cells in kidney/liver, glomerulosclerosis, proximal tubular degeneration, proteinuria; NP cells in bone marrow (zheng2016casereportrenal pages 1-3, zheng2016casereportrenal pages 3-5) Normal leukocyte acid sphingomyelinase activity (arguing against classic ASMD A/B); markedly elevated chitotriosidase; bone marrow Niemann-Pick cells; electron microscopy with massive lipid deposits in endothelial cells and podocytes (zheng2016casereportrenal pages 1-3, zheng2016casereportrenal pages 3-5) Human case report / literature review Legacy label is explicitly ambiguous; 2016 authors state the “biochemical nature of type E still awaits clarification.” This supports use as a historical descriptor rather than a molecular diagnosis (zheng2016casereportrenal pages 3-5)
Modern ASMD (historical Niemann-Pick A/B/A/B intermediate) Continuum from infantile neurovisceral to chronic visceral adult disease Very common hepatosplenomegaly; interstitial lung disease; growth delay; cytopenias; dyslipidemia with low HDL and high cholesterol/triglycerides; chronic visceral forms may survive into adulthood (geberhiwot2023consensusclinicalmanagement pages 9-11, geberhiwot2023consensusclinicalmanagement pages 17-19) Diagnosis requires markedly reduced ASM activity in leukocytes/fibroblasts; LC-MS/MS methods preferred; SMPD1 sequencing recommended for confirmation; lyso-SM is the most specific plasma biomarker, PPCS/lyso-SM509 also elevated; bone marrow foamy macrophages/sea-blue histiocytes may occur but biopsy not required (geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 9-11, geberhiwot2023consensusclinicalmanagement pages 13-14) Guideline Modern standards do not use “type E”; patients with normal ASM would not fit ASMD unless testing were misleading or incomplete. Historical adult “type E” cases with sea-blue histiocytes may overlap some chronic ASMD presentations, but molecular confirmation is needed (geberhiwot2023consensusclinicalmanagement pages 4-5, schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 11-13)
Modern NPC (historical Niemann-Pick C; D merged into NPC) Broad spectrum from neonatal fatal systemic disease to adult-onset chronic neurodegenerative disease Systemic signs often precede neurologic disease: neonatal cholestatic jaundice or isolated splenomegaly/hepatosplenomegaly; later features include vertical supranuclear gaze palsy, cerebellar ataxia, dysarthria, dysphagia, dystonia, seizures, progressive cognitive decline; adult-onset psychiatric presentations recognized (patinoescobar2019niemannpickdiseasean pages 1-2, bolton2022clinicaldiseasecharacteristics pages 6-8) Filipin staining in living skin fibroblasts shows unesterified cholesterol accumulation in lysosomes; NPC1/NPC2 genotyping confirms diagnosis, especially in variant biochemical phenotypes; NPC1 accounts for ~95% of families in the 2010 review (patinoescobar2019niemannpickdiseasean pages 1-2) Review / registry-backed review Some historical C/D/E patients were reclassified after recognition of cholesterol trafficking defects; thus some legacy “type E” patients may actually represent NPC-spectrum disease, especially if ASM is normal (schuchman2017typesaand pages 1-3, vanier1998recentadvancesin pages 10-11)
Current nosology of “type E” Obsolete historical term Earlier literature grouped some intermediate patients with hepatomegaly, foamy macrophages, partial ASM deficiency, sphingomyelin accumulation, and neurologic deterioration into C/D/E categories (schuchman2017typesaand pages 1-3) Molecular era distinguishes SMPD1-related ASMD from NPC1/NPC2-related NPC; “The nosology of types D and E NPD are no longer used” (schuchman2017typesaand pages 1-3) Review Best current practice is to avoid assigning “type E” as a final diagnosis; instead classify by enzyme assay, biomarkers, and molecular testing into ASMD, NPC, or another lysosomal disorder (schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14)

Table: This table contrasts the historical, ambiguous Niemann-Pick “type E” label with current molecularly defined entities: ASMD and NPC. It is useful for showing why NP type E should be treated as an obsolete descriptor and how modern diagnostics distinguish overlapping adult presentations.

Study / disorder context Publication date Cohort size Key quantitative findings DOI / URL Citation
International Niemann-Pick Disease Registry (INPDR), Niemann-Pick disease type C (NPC) Feb 2022 N=203 NPC patients from 6 countries Mean age at diagnosis 11.2 years; neurological-onset distribution: early infantile 24.2%, late infantile 26.4%, juvenile 23.0%, adult 20.8%, neonatal rapidly fatal systemic form 5.6%; among 97 with identified NPC1 variants, p.I1061T/c.3182T>C in 35.1% (abstract) and reported as 28.6% in extracted registry summary; splenomegaly was the most commonly reported observation and was recorded in 80% of adult patients; most common neurological manifestations: cognitive impairment 78.5%, dysarthria 75.9%, ataxia 75.9%, vertical supranuclear gaze palsy 70.9%, dysphagia 69.6%; miglustat use 62.4% (85 patients), mean duration just over 4 years; antiepileptics 32.9%, antidepressants 11.8%, antacids 9.4% (bolton2022clinicaldiseasecharacteristics pages 6-8) 10.1186/s13023-022-02200-4; https://doi.org/10.1186/s13023-022-02200-4 (bolton2022clinicaldiseasecharacteristics pages 6-8)
US real-world claims analysis, acid sphingomyelinase deficiency type B (historical Niemann-Pick type B) Mar 2023 Primary cohort N=47; sensitivity cohort N=59 70% of the primary cohort were aged <18 years; liver, spleen, and lungs were the most frequently affected organs; 28 hospitalization events in the primary cohort and 40 in the sensitivity cohort; mean length of stay 6.71 days (95% CI 2.13–9.18) in primary cohort and 4.03 days (95% CI 2.22–4.77) in sensitivity cohort; longest stays: cardiovascular 11.0 days, other liver conditions 8.3 days, cirrhosis 7.5 days; respiratory disorders mean LoS 5.71 days; medication rates in primary cohort: antibiotics 809.6 prescriptions/1000 PY (55.3% of patients), HMG-CoA inhibitors 738.0/1000 PY (12.8%), respiratory medications 666.4/1000 PY (29.8%); supplemental oxygen in 10.6%; splenectomy in 2.1%; outpatient visits driven mainly by cognitive/developmental/emotional problems and respiratory/lung disorders; respiratory/lung disorders accounted for most ED visits and hospitalizations (pulikottiljacob2023healthcareserviceuse pages 11-13, pulikottiljacob2023healthcareserviceuse pages 1-2) 10.1007/s12325-023-02453-w; https://doi.org/10.1007/s12325-023-02453-w (pulikottiljacob2023healthcareserviceuse pages 11-13, pulikottiljacob2023healthcareserviceuse pages 1-2)
Polish pediatric cohort update, chronic ASMD (visceral and neurovisceral forms) Oct 2024 N=7 Phenotype split: chronic visceral 5/7 (71%), chronic neurovisceral 2/7 (29%); splenomegaly 7/7 (100%); mild liver enlargement 4/7 (57%); interstitial lung disease on imaging 7/7 (100%); cherry-red spot 5/7 (71%); hypercholesterolemia / elevated total cholesterol, LDL-C and triglycerides 6/7 (86%); decreased HDL-C 7/7 (100%); decreased 25-hydroxy-vitamin D 7/7 (100%); thrombocytopenia present at diagnosis in 1/7 (14%), later in 3/7 total (43%); lyso-sphingomyelin in dried blood spot elevated in all screened patients, with higher values in chronic neurovisceral cases; 7 distinct SMPD1 variants identified; missense variants comprised 71% of alleles (lipinski2024chronicacidsphingomyelinase pages 4-6, lipinski2024chronicacidsphingomyelinase pages 3-4, lipinski2024chronicacidsphingomyelinase pages 1-2, lipinski2024chronicacidsphingomyelinase pages 2-3) 10.17219/acem/193696; https://doi.org/10.17219/acem/193696 (lipinski2024chronicacidsphingomyelinase pages 4-6, lipinski2024chronicacidsphingomyelinase pages 3-4, lipinski2024chronicacidsphingomyelinase pages 1-2, lipinski2024chronicacidsphingomyelinase pages 2-3)
Why these data matter for “type E” 2022–2024 contextual synthesis — Modern datasets are organized around molecularly defined entities—NPC and ASMD—not “type E.” These quantitative studies show that current research and care pathways classify patients by NPC1/NPC2-related NPC or SMPD1-related ASMD, reinforcing that historical “type E” is obsolete and should be replaced by enzyme/biomarker/genetic diagnosis (geberhiwot2023consensusclinicalmanagement pages 4-5, schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14) ASMD guideline: 10.1186/s13023-023-02686-6; https://doi.org/10.1186/s13023-023-02686-6 (geberhiwot2023consensusclinicalmanagement pages 4-5, schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14)

Table: This table compiles key 2022-2024 quantitative findings from NPC and ASMD studies that contextualize the obsolete Niemann-Pick disease type E label. It highlights how modern evidence is organized around molecularly defined disorders rather than historical subtype E.

Practical knowledge-base recommendation (implementation note)

For a Mendelian KB entry labeled “Niemann–Pick disease type E,” the evidence supports encoding it as a deprecated/historical diagnosis label with a strong directive to reclassify into ASMD vs NPC using enzyme assays, biomarkers (lyso-SM), and molecular testing (SMPD1; NPC1/NPC2). (schuchman2017typesaand pages 1-3, geberhiwot2023consensusclinicalmanagement pages 11-13, geberhiwot2023consensusclinicalmanagement pages 13-14)

References

  1. (schuchman2017typesaand pages 1-3): Edward H. Schuchman and Robert J. Desnick. Types a and b niemann-pick disease. Molecular genetics and metabolism, 120 1-2:27-33, Jan 2017. URL: https://doi.org/10.1016/j.ymgme.2016.12.008, doi:10.1016/j.ymgme.2016.12.008. This article has 412 citations and is from a peer-reviewed journal.

  2. (zheng2016casereportrenal pages 3-5): Z Zheng, C Cheng, W Zhao, Q Feng, C Li, and T Lou. Case report renal failure and ascites in a patient with niemann-pick disease: case report and literature review. Unknown journal, 2016.

  3. (geberhiwot2023consensusclinicalmanagement pages 11-13): Tarekegn Geberhiwot, Melissa Wasserstein, Subadra Wanninayake, Shaun Christopher Bolton, Andrea Dardis, Anna Lehman, Olivier Lidove, Charlotte Dawson, Roberto Giugliani, Jackie Imrie, Justin Hopkin, James Green, Daniel de Vicente Corbeira, Shyam Madathil, Eugen Mengel, Fatih Ezgü, Magali Pettazzoni, Barbara Sjouke, Carla Hollak, Marie T. Vanier, Margaret McGovern, and Edward Schuchman. Consensus clinical management guidelines for acid sphingomyelinase deficiency (niemann–pick disease types a, b and a/b). Orphanet Journal of Rare Diseases, Apr 2023. URL: https://doi.org/10.1186/s13023-023-02686-6, doi:10.1186/s13023-023-02686-6. This article has 105 citations and is from a peer-reviewed journal.

  4. (geberhiwot2023consensusclinicalmanagement pages 13-14): Tarekegn Geberhiwot, Melissa Wasserstein, Subadra Wanninayake, Shaun Christopher Bolton, Andrea Dardis, Anna Lehman, Olivier Lidove, Charlotte Dawson, Roberto Giugliani, Jackie Imrie, Justin Hopkin, James Green, Daniel de Vicente Corbeira, Shyam Madathil, Eugen Mengel, Fatih Ezgü, Magali Pettazzoni, Barbara Sjouke, Carla Hollak, Marie T. Vanier, Margaret McGovern, and Edward Schuchman. Consensus clinical management guidelines for acid sphingomyelinase deficiency (niemann–pick disease types a, b and a/b). Orphanet Journal of Rare Diseases, Apr 2023. URL: https://doi.org/10.1186/s13023-023-02686-6, doi:10.1186/s13023-023-02686-6. This article has 105 citations and is from a peer-reviewed journal.

  5. (patinoescobar2019niemannpickdiseasean pages 1-2): Bonell Patiño-Escobar, Maria H Solano, Laura Zarabanda, Claudia P Casas, and Carlos Castro. Niemann-pick disease: an approach for diagnosis in adulthood. Cureus, May 2019. URL: https://doi.org/10.7759/cureus.4767, doi:10.7759/cureus.4767. This article has 15 citations.

  6. (geberhiwot2023consensusclinicalmanagement pages 4-5): Tarekegn Geberhiwot, Melissa Wasserstein, Subadra Wanninayake, Shaun Christopher Bolton, Andrea Dardis, Anna Lehman, Olivier Lidove, Charlotte Dawson, Roberto Giugliani, Jackie Imrie, Justin Hopkin, James Green, Daniel de Vicente Corbeira, Shyam Madathil, Eugen Mengel, Fatih Ezgü, Magali Pettazzoni, Barbara Sjouke, Carla Hollak, Marie T. Vanier, Margaret McGovern, and Edward Schuchman. Consensus clinical management guidelines for acid sphingomyelinase deficiency (niemann–pick disease types a, b and a/b). Orphanet Journal of Rare Diseases, Apr 2023. URL: https://doi.org/10.1186/s13023-023-02686-6, doi:10.1186/s13023-023-02686-6. This article has 105 citations and is from a peer-reviewed journal.

  7. (geberhiwot2023consensusclinicalmanagement pages 9-11): Tarekegn Geberhiwot, Melissa Wasserstein, Subadra Wanninayake, Shaun Christopher Bolton, Andrea Dardis, Anna Lehman, Olivier Lidove, Charlotte Dawson, Roberto Giugliani, Jackie Imrie, Justin Hopkin, James Green, Daniel de Vicente Corbeira, Shyam Madathil, Eugen Mengel, Fatih Ezgü, Magali Pettazzoni, Barbara Sjouke, Carla Hollak, Marie T. Vanier, Margaret McGovern, and Edward Schuchman. Consensus clinical management guidelines for acid sphingomyelinase deficiency (niemann–pick disease types a, b and a/b). Orphanet Journal of Rare Diseases, Apr 2023. URL: https://doi.org/10.1186/s13023-023-02686-6, doi:10.1186/s13023-023-02686-6. This article has 105 citations and is from a peer-reviewed journal.

  8. (zheng2016casereportrenal pages 1-3): Z Zheng, C Cheng, W Zhao, Q Feng, C Li, and T Lou. Case report renal failure and ascites in a patient with niemann-pick disease: case report and literature review. Unknown journal, 2016.

  9. (bolton2022clinicaldiseasecharacteristics pages 6-8): Shaun C. Bolton, Vina Soran, Mercedes Pineda Marfa, Jackie Imrie, Paul Gissen, Helena Jahnova, Reena Sharma, Simon Jones, Saikat Santra, Ellen Crushell, Miriam Stampfer, Maria Jose Coll, Charlotte Dawson, Toni Mathieson, James Green, Andrea Dardis, Bruno Bembi, Marc C. Patterson, Marie T. Vanier, and Tarekegn Geberhiwot. Clinical disease characteristics of patients with niemann-pick disease type c: findings from the international niemann-pick disease registry (inpdr). Orphanet Journal of Rare Diseases, Feb 2022. URL: https://doi.org/10.1186/s13023-022-02200-4, doi:10.1186/s13023-022-02200-4. This article has 52 citations and is from a peer-reviewed journal.

  10. (geberhiwot2023consensusclinicalmanagement pages 1-2): Tarekegn Geberhiwot, Melissa Wasserstein, Subadra Wanninayake, Shaun Christopher Bolton, Andrea Dardis, Anna Lehman, Olivier Lidove, Charlotte Dawson, Roberto Giugliani, Jackie Imrie, Justin Hopkin, James Green, Daniel de Vicente Corbeira, Shyam Madathil, Eugen Mengel, Fatih Ezgü, Magali Pettazzoni, Barbara Sjouke, Carla Hollak, Marie T. Vanier, Margaret McGovern, and Edward Schuchman. Consensus clinical management guidelines for acid sphingomyelinase deficiency (niemann–pick disease types a, b and a/b). Orphanet Journal of Rare Diseases, Apr 2023. URL: https://doi.org/10.1186/s13023-023-02686-6, doi:10.1186/s13023-023-02686-6. This article has 105 citations and is from a peer-reviewed journal.

  11. (lipinski2024chronicacidsphingomyelinase pages 1-2): Patryk Lipiński, Agnieszka Ługowska, and Anna Tylki-Szymańska. Chronic acid sphingomyelinase deficiency diagnosed in infancy/childhood in polish patients: 2024 update. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 33:1163-1168, Oct 2024. URL: https://doi.org/10.17219/acem/193696, doi:10.17219/acem/193696. This article has 1 citations.

  12. (geberhiwot2023consensusclinicalmanagement pages 17-19): Tarekegn Geberhiwot, Melissa Wasserstein, Subadra Wanninayake, Shaun Christopher Bolton, Andrea Dardis, Anna Lehman, Olivier Lidove, Charlotte Dawson, Roberto Giugliani, Jackie Imrie, Justin Hopkin, James Green, Daniel de Vicente Corbeira, Shyam Madathil, Eugen Mengel, Fatih Ezgü, Magali Pettazzoni, Barbara Sjouke, Carla Hollak, Marie T. Vanier, Margaret McGovern, and Edward Schuchman. Consensus clinical management guidelines for acid sphingomyelinase deficiency (niemann–pick disease types a, b and a/b). Orphanet Journal of Rare Diseases, Apr 2023. URL: https://doi.org/10.1186/s13023-023-02686-6, doi:10.1186/s13023-023-02686-6. This article has 105 citations and is from a peer-reviewed journal.

  13. (sanchezvargas2023personalizedprecisionmedicine pages 3-4): JM Sanchez-Vargas and LJ Moreno-Giraldo. Personalized precision medicine of strategic health action in niemann-pick type a/b disease: case report. Journal of Clinical Images and Medical Case Reports, Apr 2023. URL: https://doi.org/10.52768/2766-7820/2363, doi:10.52768/2766-7820/2363. This article has 0 citations.

  14. (hovakimyan2013olfactorydeficitsin pages 1-2): Marina Hovakimyan, Anja Meyer, Jan Lukas, Jiankai Luo, Volker Gudziol, Thomas Hummel, Arndt Rolfs, Andreas Wree, and Martin Witt. Olfactory deficits in niemann-pick type c1 (npc1) disease. PLoS ONE, 8:e82216, Dec 2013. URL: https://doi.org/10.1371/journal.pone.0082216, doi:10.1371/journal.pone.0082216. This article has 47 citations and is from a peer-reviewed journal.

  15. (sarna2001patternedcerebellarpurkinje pages 1-2): Justyna Sarna, Silvia R. P. Miranda, Edward H. Schuchman, and Richard Hawkes. Patterned cerebellar purkinje cell death in a transgenic mouse model of niemann pick type a/b disease. European Journal of Neuroscience, 13:1873-1880, May 2001. URL: https://doi.org/10.1046/j.0953-816x.2001.01564.x, doi:10.1046/j.0953-816x.2001.01564.x. This article has 103 citations and is from a domain leading peer-reviewed journal.

  16. (sarna2001patternedcerebellarpurkinje pages 2-4): Justyna Sarna, Silvia R. P. Miranda, Edward H. Schuchman, and Richard Hawkes. Patterned cerebellar purkinje cell death in a transgenic mouse model of niemann pick type a/b disease. European Journal of Neuroscience, 13:1873-1880, May 2001. URL: https://doi.org/10.1046/j.0953-816x.2001.01564.x, doi:10.1046/j.0953-816x.2001.01564.x. This article has 103 citations and is from a domain leading peer-reviewed journal.

  17. (schuchman2017typesaand pages 6-8): Edward H. Schuchman and Robert J. Desnick. Types a and b niemann-pick disease. Molecular genetics and metabolism, 120 1-2:27-33, Jan 2017. URL: https://doi.org/10.1016/j.ymgme.2016.12.008, doi:10.1016/j.ymgme.2016.12.008. This article has 412 citations and is from a peer-reviewed journal.

  18. (ahmad2005allopregnanolonetreatmentboth pages 1-2): Iram Ahmad, Silvia Lope‐Piedrafita, Xiaoning Bi, Chad Hicks, Yueqin Yao, Clara Yu, Elizabeth Chaitkin, Christine M. Howison, Lyndon Weberg, Theodore P. Trouard, and Robert P. Erickson. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of niemann‐pick c mice. Journal of Neuroscience Research, 82:811-821, Dec 2005. URL: https://doi.org/10.1002/jnr.20685, doi:10.1002/jnr.20685. This article has 100 citations and is from a peer-reviewed journal.

  19. (pulikottiljacob2023healthcareserviceuse pages 1-2): Ruth Pulikottil-Jacob, Michael L. Ganz, Marie Fournier, and Natalia Petruski-Ivleva. Healthcare service use patterns among patients with acid sphingomyelinase deficiency type b: a retrospective us claims analysis. Advances in Therapy, 40:2234-2248, Mar 2023. URL: https://doi.org/10.1007/s12325-023-02453-w, doi:10.1007/s12325-023-02453-w. This article has 8 citations and is from a peer-reviewed journal.

  20. (pulikottiljacob2023healthcareserviceuse pages 11-13): Ruth Pulikottil-Jacob, Michael L. Ganz, Marie Fournier, and Natalia Petruski-Ivleva. Healthcare service use patterns among patients with acid sphingomyelinase deficiency type b: a retrospective us claims analysis. Advances in Therapy, 40:2234-2248, Mar 2023. URL: https://doi.org/10.1007/s12325-023-02453-w, doi:10.1007/s12325-023-02453-w. This article has 8 citations and is from a peer-reviewed journal.

  21. (lipinski2024chronicacidsphingomyelinase pages 4-6): Patryk Lipiński, Agnieszka Ługowska, and Anna Tylki-Szymańska. Chronic acid sphingomyelinase deficiency diagnosed in infancy/childhood in polish patients: 2024 update. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 33:1163-1168, Oct 2024. URL: https://doi.org/10.17219/acem/193696, doi:10.17219/acem/193696. This article has 1 citations.

  22. (vanier1998recentadvancesin pages 10-11): Marie T. Vanier and Kinuko Suzuki. Recent advances in elucidating niemann‐pick c disease. Brain Pathology, 8:163-174, Jan 1998. URL: https://doi.org/10.1111/j.1750-3639.1998.tb00143.x, doi:10.1111/j.1750-3639.1998.tb00143.x. This article has 147 citations and is from a domain leading peer-reviewed journal.

  23. (lipinski2024chronicacidsphingomyelinase pages 3-4): Patryk Lipiński, Agnieszka Ługowska, and Anna Tylki-Szymańska. Chronic acid sphingomyelinase deficiency diagnosed in infancy/childhood in polish patients: 2024 update. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 33:1163-1168, Oct 2024. URL: https://doi.org/10.17219/acem/193696, doi:10.17219/acem/193696. This article has 1 citations.

  24. (lipinski2024chronicacidsphingomyelinase pages 2-3): Patryk Lipiński, Agnieszka Ługowska, and Anna Tylki-Szymańska. Chronic acid sphingomyelinase deficiency diagnosed in infancy/childhood in polish patients: 2024 update. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 33:1163-1168, Oct 2024. URL: https://doi.org/10.17219/acem/193696, doi:10.17219/acem/193696. This article has 1 citations.

Artifacts